Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression ... The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato ...
Hosted on MSN2mon
FDA Clears Spravato For Monotherapy Depression TreatmentsThe Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato ...
The FDA approval comes after a priority review and is based on the ... which showed that Spravato administered as a nasal spray achieved a rapid and statistically significant improvement in ...
The remaining 20% is their coinsurance. S-ketamine, or esketamine (Spravato), is an FDA-approved nasal spray that doctors and healthcare professionals may prescribe for major depressive disorder ...
The analyst equates COMP360 to Spravato 2.0. Johnson & Johnson’s JNJ Spravato (esketamine) is a nasal spray for TRD and major depressive disorder (MDD), selling over ~$1 billion annually.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback